Amisulpride in the Treatment of Schizophrenia

被引:0
|
作者
Ustohal, Libor [1 ,2 ]
机构
[1] CEITEC MU, Brno, Czech Republic
[2] LF MU & FN Brno, Psychiat Klin, Brno 62500, Czech Republic
关键词
amisulpride; schizophrenia; positive symptoms; negative symptoms; CLOZAPINE-INDUCED HYPERSALIVATION; CONTROLLED-TRIAL; DOUBLE-BLIND; ANTIPSYCHOTICS; IMPROVEMENT; OLANZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; RECEPTORS;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Amisulpride is a second generation D2 and D3 receptor blocking antipsychotic agent. It has so called biphasic affect - low doses increase and higher doses decrease dopaminergic neurotransmission. It has proven efficacy in the treatment of positive as well as negative symptoms of schizophrenia and, it is assumed that it also impacts on affective (depressive) symptoms and cognitive dysfunction. Amisulpride is effective as monotherapy although some evidence also exists of its efficacy when used in combinations, namely in combination with clozapine and, alternatively, olanzapine. It has only a few contraindications and, due to relatively low number of side-effects, is well-tolerated.
引用
下载
收藏
页码:706 / 708
页数:3
相关论文
共 50 条
  • [21] A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
    Abdall-Razak, Ali
    Macaulay, Alex
    Tiefenbach, Jakov
    Borges, Karen
    Mathema, Sina
    Zuberi, Sameer
    HELIYON, 2019, 5 (09)
  • [22] Naturalistic treatment of positive symptoms in schizophrenia with amisulpride:: Are there gender differences?
    Müller, MJ
    Regenbogen, B
    Sachse, J
    Härtter, S
    Hiemke, C
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 249 - 249
  • [23] Impact of the treatment with amisulpride in patients with schizophrenia and schizophrenic mood disorder
    Ojeda, GM
    Valverde, JIF
    Garrote, JAB
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S254 - S254
  • [24] Efficacy of amisulpride, aripiprazole and ziprasidone in the treatment of negative symptoms in schizophrenia
    Gheorghe, M.
    Grigorescu, G.
    Baloescu, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S471 - S471
  • [25] Amisulpride augmentation of clozapine effect in patients with treatment resistant schizophrenia
    Matthiasson, P
    Munro, JC
    Travis, MJ
    Osborne, SA
    Purcell, S
    Cobb, AM
    Beer, MD
    Kerwin, RW
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 209 - 209
  • [26] Successful treatment with amisulpride for the progression of olfactory reference syndrome to schizophrenia
    Yeh, Yi-Wei
    Chen, Chih-Kang
    Huang, San-Yuan
    Kuo, Shin-Chang
    Chen, Chun-Yen
    Chen, Chih-Lun
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (03): : 579 - 580
  • [27] Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
    Peuskens, J
    Bech, P
    Möller, HJ
    Bale, R
    Fleurot, O
    Rein, W
    PSYCHIATRY RESEARCH, 1999, 88 (02) : 107 - 117
  • [28] Clozapine with amisulpride for refractory schizophrenia
    Agelink, MW
    Kavuk, I
    Ak, I
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (05): : 924 - 925
  • [29] AMISULPRIDE AUGMENTATION OF CLOZAPINE FOR TREATMENT-REFRACTORY SCHIZOPHRENIA: THE AMICUS STUDY
    Barnes, Thomas
    Leeson, Verity
    Paton, Carol
    Marston, Louise
    Osborn, David
    Kumar, Raj
    Keown, Patrick
    Zafar, Rameez
    Iqbal, Khalid
    Singh, Vineet
    Fridrich, Pavel
    Fitzgerald, Zachary
    Bagalkote, Hemant
    Haddad, Peter
    Husni, Mariwan
    Amos, Tim
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S164 - S165
  • [30] White matter connectivity related to amisulpride treatment response in patients with schizophrenia
    Kim, J. H.
    Choi, T. K.
    Lee, S. H.
    Kim, M. K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S701 - S702